Malaria Vaccines Get a Shot in the Arm

MVI announces $156 million grant from Bill & Melinda Gates Foundation to support essential vaccine role in strategy to eradicate malaria.

Read more »

Biting Back? A Radical Approach to Stopping the Spread of Malaria: Immunize Mosquitoes

Transmission-blocking vaccines would help protect mosquitoes from getting infected with malaria.

Read more »

© London School of Hygiene and Tropical Medicine

Partnering with us

PuzzleWe are pursuing a range of vaccine development approaches with an expanding circle of industry, academic, and government partners.

Our portfolio

MVI portfolioWe maintain a diverse portfolio of projects, including preclinical feasibility studies, translational projects, and one advanced clinical project.

View the portfolio »

What we do and how we do it

MVI overview imageWe identify potentially promising malaria vaccine approaches and systematically move them through the development process. At the same time, we work to catalyze access to a successful malaria vaccine in the countries that need it most.

Read more »


 

News and announcements

Gates Foundation commits more than $500 million to tackle the burden of infectious disease in developing countries

In an address to American Society of Tropical Medicine and Hygiene, Bill Gates says that the Ebola epidemic underscores the urgent need for R&D to stay ahead of emerging disease threats, and declares that new drugs, diagnostics, and vaccines can eradicate malaria by the middle of the 21st Century.

 

Japan's Global Health Innovative Technology Fund announces award to MVI

MVI welcomes announcement by Japan’s Global Health Innovative Technology Fund of a grant to MVI and its partner Ehime University to fast-track the development of a novel malaria vaccine candidate. The new vaccine approach is targeted at blocking malaria parasite transmission between humans and mosquitoes.

 

GSK announces EU regulatory submission for RTS,S malaria vaccine candidate

The regulatory application to the European Medicines Agency (EMA) will follow the Article 58 procedure, which allows the EMA to assess the quality, safety and efficacy of a candidate vaccine, or medicine, manufactured in a European Union (EU) member state for a disease recognized by the World Health Organization as of major public health interest, but intended exclusively for use outside the EU.

 

Events and Conferences

ASTMH 63nd Annual Meeting
November 2–6, 2014